All In Biotech

Drug Trial Radar · NCT00808067

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

Last checked: Nov 20, 2026Latest source record: Jun 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,897 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,897

Actual

Start

Nov 2008

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes

Conditions

  • Atrial Fibrillation

Interventions

  • dabigatran dose 1Drug

    dabigatran high dose twice daily

  • dabigatran dose 2Drug

    dabigatran low dose twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Bleeding, Annualized Rate of Subjects With Major BleedsTime frame: up to 43 months

Locations

567 sites in 35 countries. Site status is shown where the registry gives one.

  • 1160.71.0046 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.71.0057 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.71.0211 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 1160.71.0115 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 1160.71.0104 Boehringer Ingelheim Investigational Site

    Lake Havasu City, Arizona

  • 1160.71.0185 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 1160.71.0038 Boehringer Ingelheim Investigational Site

    Hot Springs, Arkansas

  • 1160.71.0302 Boehringer Ingelheim Investigational Site

    Jonesboro, Arkansas

  • 1160.71.0191 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.71.0213 Boehringer Ingelheim Investigational Site

    Little Rock, Arkansas

  • 1160.71.0441 Boehringer Ingelheim Investigational Site

    Carmichael, California

  • 1160.71.0333 Boehringer Ingelheim Investigational Site

    Fullerton, California

  • 1160.71.0384 Boehringer Ingelheim Investigational Site

    La Jolla, California

  • 1160.71.0246 Boehringer Ingelheim Investigational Site

    Lancaster, California

  • 1160.71.0070 Boehringer Ingelheim Investigational Site

    Merced, California

  • 1160.71.0349 Boehringer Ingelheim Investigational Site

    Oakland, California

  • 1160.71.0016 Boehringer Ingelheim Investigational Site

    Oceanside, California

  • 1160.71.0459 Boehringer Ingelheim Investigational Site

    Pasadena, California

  • 1160.71.0270 Boehringer Ingelheim Investigational Site

    Poway, California

  • 1160.71.0135 Boehringer Ingelheim Investigational Site

    Riverside, California

  • 1160.71.0300 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 1160.71.0284 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1160.71.0379 Boehringer Ingelheim Investigational Site

    Walnut Creek, California

  • 1160.71.0321 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1160.71.0449 Boehringer Ingelheim Investigational Site

    Colorado Springs, Colorado

  • 1160.71.0360 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1160.71.0413 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 1160.71.0362 Boehringer Ingelheim Investigational Site

    Fort Collins, Colorado

  • 1160.71.0278 Boehringer Ingelheim Investigational Site

    Bridgeport, Connecticut

  • 1160.71.0482 Boehringer Ingelheim Investigational Site

    Guilford, Connecticut

  • 1160.71.0382 Boehringer Ingelheim Investigational Site

    Boynton Beach, Florida

  • 1160.71.0056 Boehringer Ingelheim Investigational Site

    Brandon, Florida

  • 1160.71.0296 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 1160.71.0327 Boehringer Ingelheim Investigational Site

    Coral Springs, Florida

  • 1160.71.0376 Boehringer Ingelheim Investigational Site

    Daytona Beach, Florida

  • 1160.71.0074 Boehringer Ingelheim Investigational Site

    Fort Myers, Florida

  • 1160.71.0089 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1160.71.0232 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1160.71.0427 Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • 1160.71.0012 Boehringer Ingelheim Investigational Site

    Lakeland, Florida

Showing 40 of 567 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.